Advertisement

Topics

J&J Wins FDA Nod for Erleada, the First Drug for Nonmetastatic Prostate Cancer

19:00 EST 14 Feb 2018 | BioSpace

Approval is based on Phase 3 SPARTAN clinical trial data which showed the drug decreased the risk of distant metastasis or death by 72 percent.

Original Article: J&J Wins FDA Nod for Erleada, the First Drug for Nonmetastatic Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "J&J Wins FDA Nod for Erleada, the First Drug for Nonmetastatic Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...